Continuing Medical Education Program – Purchase Activities

The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for healthcare professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs and changes in therapeutics. The objectives of the program are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter CME Program is funded by fees paid by the activity participants. The Medical Letter is free of commercial influence and financial sponsorship.

The Medical Letter Individual Activities — Online Only

I would like to order the following Per Issue Activities eligible for 2 credits each:

$15 per activity
3 or more: $10/activity

	1691 (2 credits) Expires 11/28/2024 Drugs for Depression

	1692 (2 credits) Expires 12/12/2024 Zuranolone (Zurzuvae) - An Oral Drug for Postpartum Depression Vonoprazan (Voquezna) for Erosive Esophagitis Tirzepatide (Zepbound) for Chronic Weight Management Three New Injectable Antipsychotic Drugs

	1693 (2 credits) Treatment of Atrial Fibrillation

	1694 (2 credits) Casgevy and Lyfgenia: Two Gene Therapies for Sickle Cell Disease Bimekizumab (Bimzelx) for Psoriasis Perfluorohexyloctane Ophthalmic Solution (Miebo) for Dry Eye Disease Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration

	1695 (2 credits) Drugs for Acne Drugs for Rosacea IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure

	1696 (2 credits) Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum Rozanolixizumab (Rystiggo) for Myasthenia Gravis Balfaxar: Another Four-Factor PCC for Warfarin Reversal

	1697 (2 credits) Drugs for Menopausal Symptoms Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease

	1698 (2 credits) Airsupra: An Inhaled Albuterol/Budesonide Combination for Asthma Penbraya: A Pentavalent Meningococcal Vaccine Mirikizumab (Omvoh) for Ulcerative Colitis A New OTC Naloxone Nasal Spray (RiVive)

	1699 (2 credits) Drugs for Bipolar Disorder Omalizumab (Xolair) for Food Allergy

	1700 (2 credits) Roflumilast Foam (Zoryve) for Seborrheic Dermatitis Cabtreo: A Three-Drug Gel for Acne Zilucoplan (Zilbrysq) for Myasthenia Gravis Donislecel (Lantidra) for Type 1 Diabetes

	1701 (2 credits) Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis A New Indication for Semaglutide (Wegovy) Intravenous Acetaminophen/Ibuprofen (Combogesic IV) iDose TR - A Travoprost Implant for Glaucoma Antibiotic Prophylaxis for Dental Procedures

	1702 (2 credits) Sotatercept (Winrevair) for Pulmonary Arterial Hypertension A New Indication for Bempedoic Acid (Nexletol) Sarilumab (Kevzara) for Polymyalgia Rheumatica In Brief: Casgevy for Beta Thalassemia COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis

	1703 (2 credits) Drugs for Hypertension

	1704 (2 credits) Drugs for Head Lice Aprocitentan (Tryvio) for Hypertension Budesonide Oral Suspension (Eohilia) for Eosinophilic Esophagitis Beqvez - Another Gene Therapy for Hemophilia B

	1705 (2 credits) Gepirone (Exxua) for Depression Lotilaner (Xdemvy) for Demodex Blepharitis Ophthalmic Phentolamine (Ryzumvi) for Drug-Induced Mydriasis Rezafungin (Rezzayo) for Invasive Candida Infections

	1706 (2 credits) Drugs for Postmenopausal Osteoporosis

	1707 (2 credits) In Brief: RSV Vaccine (Arexvy) for Ages 50-59 Iloprost (Aurlumyn) for Frostbite Iloperidone (Fanapt) - A New Indication for Bipolar Disorder Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections In Brief: Doxycycline for STI Post-Exposure Prophylaxis

	1708 (2 credits) Drugs for Epilepsy

	1709 (2 credits) Donanemab (Kisunla) for Alzheimer's Disease Ensifentrine (Ohtuvayre) for COPD Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis Ryzneuta for Prevention of Febrile Neutropenia Expanded Indication for Elevidys

	1710 (2 credits) Drugs for COPD

	1711 (2 credits) Influenza Vaccine for 2024-2025 Roflumilast Cream (Zoryve) for Atopic Dermatitis COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025

	1712 (2 credits) Drugs for Plaque Psoriasis

	1713 (2 credits) Capvaxive - A 21-Valent Pneumococcal Conjugate Vaccine An Epinephrine Nasal Spray (neffy) for Anaphylaxis Vonoprazan (Voquezna) for Nonerosive GERD A New RSV Vaccine (mResvia) for Adults 60 Years or Older

	1714 (2 credits) Drugs for Hepatitis C Virus Infection In Brief: Subcutaneous Ocrelizumab (Ocrevus Zunovo) for Multiple Sclerosis

	1715 (2 credits) Xanomeline/Trospium (Cobenfy) for Schizophrenia Lebrikizumab (Ebglyss) for Atopic Dermatitis Eroxon - An OTC Gel for Erectile Dysfunction Risankizumab (Skyrizi) for Ulcerative Colitis

	1716 (2 credits) Drugs for Asthma

Add to Cart

ACCME The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Your participation information will be shared with ABIM through PARS.

ABS CC Successful completion of this CME activity enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

AAFP The AAFP has reviewed The Medical Letter Continuing Medical Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2024 to 12/31/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

Accreditation Council on Pharmacy Education
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Each exam is acceptable for 2.0 hours of knowledge-based continuing education credit (0.2 CEU).